MA27747A1 - Dérivés azabicycliques à substituants pyridyloxyméthyle et benzisoxazole - Google Patents
Dérivés azabicycliques à substituants pyridyloxyméthyle et benzisoxazoleInfo
- Publication number
- MA27747A1 MA27747A1 MA28495A MA28495A MA27747A1 MA 27747 A1 MA27747 A1 MA 27747A1 MA 28495 A MA28495 A MA 28495A MA 28495 A MA28495 A MA 28495A MA 27747 A1 MA27747 A1 MA 27747A1
- Authority
- MA
- Morocco
- Prior art keywords
- alkoxy
- group
- benzisoxazole
- alkyl
- pyridyloxymethyl
- Prior art date
Links
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical group C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 title abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- -1 aminomethylpyridyloxymethyl Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Dérivés azabicycliques à substituants pyridyloxymethyle et benzisoxazole Un composé azabicyclique à substituant aminométhylpyridyloxyméthyle/benzisoxazole répondant à la formule (I), une composition pharmaceutique le comprenant, et une méthode de traitement d'un ou de plusieurs troubles du SNC ou d'autres troubles, y compris le traitement conjoint de troubles tels que la schizophrénie et la dépression. Ou son énantiomère (R) ou (S), ou son isomère cis ou trans, ou un sel, produit de solvatation ou précurseur médicamenteux pharmaceutiquement acceptable, de celui-ci ou de n'importe laquelle des entités précédentes, formule dans laquelle m est égal à 0 ou 1, Z représente un groupe (II) dans lequel R7 représente un atome d'hydrogène ou un groupe alkoxy en C1 à C3 ; R8 représente un atome d'hydrogène, un groupe hydroxy ou alkoxy en C1 à C3 ; et R9 représente un groupe alkoxy en C1 à C3 ; X représente un atome d'oxygène ou un groupe NR, dans lequel R représente un atome d'hydrogène ou un groupe alkyle en C1 à C6 ; Y représente un groupe méthylène, lorsque n est égal à 0, 1. ou 2 ; ou un atome d'oxygène, d'azote ou de soufre, lorsque n est égal à 2, 3 ou 4 ; R1 et R2 représentent chacun indépendamment un atome d'hydrogène, un atome d'halogène ou un groupe alkyle en C1 à C6, alkoxy en C1 à C6 ou (alkoxy en C1 à C6) (alkyle en C1 à C6), n'importe lequel de ces groupes pouvant être non substitué ou substitué avec un ou plusieurs halogènes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45392503P | 2003-03-12 | 2003-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27747A1 true MA27747A1 (fr) | 2006-02-01 |
Family
ID=32990837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28495A MA27747A1 (fr) | 2003-03-12 | 2005-09-12 | Dérivés azabicycliques à substituants pyridyloxyméthyle et benzisoxazole |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7345038B2 (fr) |
| EP (1) | EP1608648B1 (fr) |
| JP (2) | JP3910627B2 (fr) |
| KR (2) | KR100767854B1 (fr) |
| CN (1) | CN100389115C (fr) |
| AP (1) | AP2005003390A0 (fr) |
| AR (1) | AR043537A1 (fr) |
| AU (2) | AU2004220327B2 (fr) |
| BR (1) | BRPI0408248A (fr) |
| CA (1) | CA2518740C (fr) |
| EA (1) | EA009527B1 (fr) |
| EC (1) | ECSP056011A (fr) |
| GT (1) | GT200400041A (fr) |
| HR (1) | HRP20050798A2 (fr) |
| IL (1) | IL170290A (fr) |
| MA (1) | MA27747A1 (fr) |
| MX (1) | MXPA05009660A (fr) |
| NL (1) | NL1025710C2 (fr) |
| NO (1) | NO20054095L (fr) |
| OA (1) | OA13038A (fr) |
| PA (1) | PA8597501A1 (fr) |
| PE (1) | PE20041057A1 (fr) |
| PL (1) | PL378749A1 (fr) |
| RS (1) | RS20050692A (fr) |
| TN (1) | TNSN05224A1 (fr) |
| TW (1) | TW200502234A (fr) |
| UA (1) | UA78437C2 (fr) |
| UY (1) | UY28225A1 (fr) |
| WO (1) | WO2004081007A1 (fr) |
| ZA (1) | ZA200506373B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6994726B2 (en) * | 2004-05-25 | 2006-02-07 | Calcitec, Inc. | Dual function prosthetic bone implant and method for preparing the same |
| ES2372694T3 (es) * | 2003-10-15 | 2012-01-25 | OSI Pharmaceuticals, LLC | Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina. |
| WO2005082370A1 (fr) * | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | Combinaisons d'un antipsychotique atypique et de derives azabicycliques d'aminomethylpyridyloxy- methyle/benzisoxazole pour le traitement de troubles du systeme nerveux central |
| HRP20090495T1 (hr) * | 2004-04-02 | 2009-10-31 | Osi Pharmaceuticals | Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom |
| AR053090A1 (es) | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos |
| JP2008512441A (ja) * | 2004-09-10 | 2008-04-24 | ファイザー・プロダクツ・インク | ピリジルオキシメチル、及びベンズイソオキサゾール・アザビシクロ誘導体を使用する、認知障害の治療方法 |
| US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
| JP2011510018A (ja) * | 2008-01-18 | 2011-03-31 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 癌治療のためのイミダゾピラジノール誘導体 |
| EP2283020B8 (fr) * | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Imidazopyrazines et imidazotriazines substituées |
| CN102405214A (zh) | 2009-04-20 | 2012-04-04 | Osi药物有限责任公司 | C-吡嗪-甲胺的制备 |
| JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 副腎皮質癌を治療するためのｏｓｉ−９０６の使用 |
| US9394290B2 (en) * | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
| WO2014078568A1 (fr) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Méthodes et compositions pour le traitement de la schizophrénie |
| US9980945B2 (en) | 2015-01-13 | 2018-05-29 | Vanderbilt University | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| WO2020183011A1 (fr) | 2019-03-14 | 2020-09-17 | Institut Curie | Inhibiteurs de htr1d et leurs utilisations dans le traitement du cancer |
| WO2023083445A1 (fr) | 2021-11-10 | 2023-05-19 | Symrise Ag | Compositions comprenant des agents de refroidissement agonistes de trpm8 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX19222A (es) | 1989-01-23 | 1993-12-01 | Pfizer | Agentes ansioliticos bis-aza-biciclicos |
| US5167034A (en) * | 1990-06-18 | 1992-11-24 | International Business Machines Corporation | Data integrity for compaction devices |
| US5157034A (en) | 1991-02-27 | 1992-10-20 | Pfizer Inc. | Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines |
| CA2118936A1 (fr) | 1991-09-25 | 1993-04-01 | Gene M. Bright | Derives de substitution en 2 de perhydro-1-h-pyrido[1,2-a]pyrazines, agent neuroleptiques |
| ATE185565T1 (de) | 1992-06-16 | 1999-10-15 | Pfizer | Verfahren und zwischenprodukte zur herstellung von bis-aza-bicyclischen anxiolytica |
| US5731307A (en) | 1994-09-30 | 1998-03-24 | Pfizer, Inc. | Neuroleptic 2,7-disubtituted perhydro-1h-pyrido 1, 2-A!pyrazines |
| CA2289574C (fr) | 1997-05-30 | 2007-04-24 | Neurosearch A/S | Derives de 8-azabicyclo[3.2.1]oct-2-ene et -octane utilises comme ligands cholinergiques de recepteurs nicotiniques de l'ach |
| PA8469101A1 (es) * | 1998-04-09 | 2000-09-29 | Pfizer Prod Inc | Ligandos azabiciclicos de receptores 5ht1 |
| SK2612001A3 (en) | 1998-08-26 | 2001-11-06 | Aventis Pharma Ltd | Aza-bicycles which modulate the inhibition of cell adhesion |
| HK1039326A1 (zh) | 1998-09-18 | 2002-04-19 | Abbott Gmbh & Co. Kg | 4氨基吡咯并嘧啶作为激酶抑制剂 |
| HK1039325B (en) | 1998-09-18 | 2006-02-24 | Abbott Gmbh & Co. Kg | 4-aminopyrrolopyrimidines as kinase inhibitors |
| UA62015C2 (en) * | 1998-12-28 | 2003-12-15 | Pfizer Prod Inc | Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants) |
| HUP0202248A3 (en) | 1999-03-12 | 2006-06-28 | Boehringer Ingelheim Pharma | Compounds useful as anti-inflammatory agents |
| EP1177792A3 (fr) * | 2000-07-27 | 2002-10-23 | Pfizer Products Inc. | Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute |
-
2004
- 2004-02-23 AP AP2005003390A patent/AP2005003390A0/xx unknown
- 2004-02-23 KR KR1020057016859A patent/KR100767854B1/ko not_active Expired - Fee Related
- 2004-02-23 JP JP2006506261A patent/JP3910627B2/ja not_active Expired - Fee Related
- 2004-02-23 PL PL378749A patent/PL378749A1/pl not_active Application Discontinuation
- 2004-02-23 CA CA2518740A patent/CA2518740C/fr not_active Expired - Fee Related
- 2004-02-23 EA EA200501148A patent/EA009527B1/ru not_active IP Right Cessation
- 2004-02-23 EP EP04713592A patent/EP1608648B1/fr not_active Expired - Lifetime
- 2004-02-23 CN CNB2004800066516A patent/CN100389115C/zh not_active Expired - Fee Related
- 2004-02-23 WO PCT/IB2004/000499 patent/WO2004081007A1/fr not_active Ceased
- 2004-02-23 MX MXPA05009660A patent/MXPA05009660A/es active IP Right Grant
- 2004-02-23 UA UAA200508639A patent/UA78437C2/uk unknown
- 2004-02-23 OA OA1200500259A patent/OA13038A/en unknown
- 2004-02-23 AU AU2004220327A patent/AU2004220327B2/en not_active Ceased
- 2004-02-23 HR HR20050798A patent/HRP20050798A2/hr not_active Application Discontinuation
- 2004-02-23 BR BRPI0408248-6A patent/BRPI0408248A/pt not_active IP Right Cessation
- 2004-02-23 KR KR1020077013527A patent/KR20070074667A/ko not_active Withdrawn
- 2004-02-23 RS YUP-2005/0692A patent/RS20050692A/sr unknown
- 2004-03-08 PA PA20048597501A patent/PA8597501A1/es unknown
- 2004-03-09 PE PE2004000256A patent/PE20041057A1/es not_active Application Discontinuation
- 2004-03-10 AR ARP040100770A patent/AR043537A1/es not_active Application Discontinuation
- 2004-03-11 UY UY28225A patent/UY28225A1/es not_active Application Discontinuation
- 2004-03-11 GT GT200400041A patent/GT200400041A/es unknown
- 2004-03-11 TW TW093106481A patent/TW200502234A/zh unknown
- 2004-03-12 US US10/800,328 patent/US7345038B2/en not_active Expired - Fee Related
- 2004-03-12 NL NL1025710A patent/NL1025710C2/nl not_active IP Right Cessation
-
2005
- 2005-08-10 ZA ZA200506373A patent/ZA200506373B/en unknown
- 2005-08-15 IL IL170290A patent/IL170290A/en not_active IP Right Cessation
- 2005-09-02 NO NO20054095A patent/NO20054095L/no unknown
- 2005-09-12 MA MA28495A patent/MA27747A1/fr unknown
- 2005-09-12 TN TNP2005000224A patent/TNSN05224A1/fr unknown
- 2005-09-12 EC EC2005006011A patent/ECSP056011A/es unknown
-
2006
- 2006-10-26 JP JP2006291545A patent/JP2007051155A/ja active Pending
-
2010
- 2010-07-23 AU AU2010203303A patent/AU2010203303A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN05224A1 (fr) | Derives azabicycliques a substituants pyridyloxymethyle et benzisoxazole | |
| CA2662848C (fr) | Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique | |
| MA26996A1 (fr) | Derives de glutaramide a substituant n-phenpropylcyclopentyle, servant d'inhibiteurs de nep pour un trouble d'eveil sexuel feminin | |
| CA2397636A1 (fr) | Derives amines de dihydro-1,3,5-triazine et leurs applications en therapeutique | |
| MA27796A1 (fr) | Composes n-heterocycliques condenses et leur utilisation comme antagonistes des recepteurs de crf | |
| CA2203618A1 (fr) | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| CA2481461A1 (fr) | Derives de n-[phenyl(piperidin-2-yl) methyl] benzamide, leur preparation et leur application en therapeutique | |
| MA32088B1 (fr) | Dérivés bicycliques de carboxamides azabicycliques, leur préparation et leur application en thérapeutique | |
| MA26952A1 (fr) | Derives d'imidazole a noyau aryle ou heteroaryle condense, utiles comme agents anti-inflammatoires et analgesiques. | |
| MA28271A1 (fr) | Dérivés de benzènesulfonylamino-pyridine -2-yle et composés apparentés servant d'inhibiteurs de la 11-bêta- hydroxystéroïde-déshydrogénase de type 1(11-bêta-HSD-1)pour le traitement du diabète et de l'obésité | |
| TNSN07178A1 (fr) | N-sulfonylaminobenzyl-2-phenoxy-acetamides substitues | |
| MA28438B1 (fr) | Derives azabicyclo (3.1.0) hexane utiles comme modulateurs des recepteurs d3 de la dopamine | |
| EP0385850A3 (fr) | Nouveaux dérivés de benzimidazoles et azabenzimidazoles, leurs procédés de préparation, intermédiaires de synthèse, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et les ulcères duodénaux | |
| TNSN06360A1 (fr) | 4-phenylamino-quinazoline-6-yl-amides | |
| MA28684B1 (fr) | 1-aza-bicyclo[3.3.1]nonanes | |
| MA27247A1 (fr) | Utilisation combinee de derive indolopyrrolocarbazole antitumoral et autre agent antitumoral | |
| FR2866647A1 (fr) | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| MA31674B1 (fr) | Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique | |
| MA30209B1 (fr) | Derives de l'acide benzo(f)isoindol-2-ylphenyl acetique comme agonistes du recepteur ep 4 | |
| MA31620B1 (fr) | Perfectionnements de ou concernant des composes organiques | |
| MA30577B1 (fr) | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques | |
| CA2161297A1 (fr) | Nouveaux derives de la diosmetine, leur procede de preparation et les compositions pharmaceutiques les contenant | |
| FR2854634A1 (fr) | Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| MA30308B1 (fr) | Dérivés de benzoisoindole utilisés dans le traitement de la douleur | |
| WO2001044207B1 (fr) | Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2 4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant |